Search - tctmd.com

Displaying 421 - 440 of 1656

Sort: Relevancy | Date

News Industry News

Medtronic Receives CE Mark for New Single-Chamber ICDs That Can Detect Atrial Fibrillation

October 21, 2015

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

Shelley Wood

October 20, 2015

News Industry News

First Patient Enrolled in the SMILE Study, Sensible Medical Innovation's Randomized Controlled Trial (RCT) Designed to Measure ReDS™ Technology Impact on Heart Failure Rehospitalizations

October 20, 2015

Presentation TCT 2015

First-in-Man Experience With Human Embryonic Stem Cell-Derived Progenitors for Heart Failure

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Philippe Menasché

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? Yes, Mesenchymal Cells Are Ready to Be Tested for Prevention and Treatment of Chronic Ischemic and Nonischemic Heart Failure!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Emerson C. Perin

October 15, 2015

Presentation TCT 2015

Stem CellBased Ablation for Ventricular Arrhythmias

Presenter: Nabil Dib, Philippe Menasché, Angel Arenal

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

Presenter: Nabil Dib, Philippe Menasché, Marc S. Penn

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiac Progenitor Cells Are the Only One!

Presenter: Nabil Dib, Philippe Menasché, Timothy D. Henry

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Combination of Cells for Additive Effects: This Is the Key!

Presenter: Nabil Dib, Philippe Menasché, Jay H Traverse

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiopoietic Commitment Is the Key!

Presenter: Nabil Dib, Philippe Menasché, Amit Patel

October 15, 2015

Presentation TCT 2015

Cell-Based Therapies to Prevent and Cure Heart Failure: More Than an Adventure

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Douglas W. Losordo

October 15, 2015

News Industry News

Study Shows Initial Aortic Valve Replacement In Asymptomatic Patients With Severe Aortic Stenosis May be Viable Treatment Option

October 15, 2015

News Conference News TCT 2015

Initial Surgical AVR Improves Long-term Outcomes in Asymptomatic Patients With Severe AS

October 15, 2015

Presentation TCT 2015

Cell Therapy for CHF

Presenter: Henricus J. Duckers, Bernard J. Gersh, Timothy D. Henry

October 14, 2015

Presentation TCT 2015

Gene Therapy for CHF

Presenter: Henricus J. Duckers, Bernard J. Gersh, Gary L. Schaer

October 14, 2015

Presentation TCT 2015

CPulse

Presenter: Valluvan Jeevanandam, Ulrich P. Jorde, Dimitrios Georgakopoulos

October 14, 2015

Presentation TCT 2015

Case Introduction: A Decompensated Patient With Heart Failure and Hypotension

Presenter: Valluvan Jeevanandam, Ulrich P. Jorde

October 14, 2015

Presentation TCT 2015

Latest Innovations in ECMO and Escalation of Therapy

Presenter: Valluvan Jeevanandam, Ulrich P. Jorde, Jonathan M. Hill

October 14, 2015

Presentation TCT 2015

Durable Ventricular Assist Devices: Current and Next-Generation Devices and Implantation Techniques

Presenter: Valluvan Jeevanandam, Ulrich P. Jorde

October 14, 2015

Presentation TCT 2015

NuPulse iVAS - A Minimally Invasive Advanced CHF Device

Presenter: Valluvan Jeevanandam, Ulrich P. Jorde

October 14, 2015

Advertisement

Medtronic Receives CE Mark for New Single-Chamber ICDs That Can Detect Atrial Fibrillation

My Takeaways From TCT 2015

First Patient Enrolled in the SMILE Study, Sensible Medical Innovation's Randomized Controlled Trial (RCT) Designed to Measure ReDS™ Technology Impact on Heart Failure Rehospitalizations

First-in-Man Experience With Human Embryonic Stem Cell-Derived Progenitors for Heart Failure

Debate: Are We Really Ready for Phase III Trials? Yes, Mesenchymal Cells Are Ready to Be Tested for Prevention and Treatment of Chronic Ischemic and Nonischemic Heart Failure!

Stem CellBased Ablation for Ventricular Arrhythmias

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiac Progenitor Cells Are the Only One!

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Combination of Cells for Additive Effects: This Is the Key!

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiopoietic Commitment Is the Key!

Cell-Based Therapies to Prevent and Cure Heart Failure: More Than an Adventure

Study Shows Initial Aortic Valve Replacement In Asymptomatic Patients With Severe Aortic Stenosis May be Viable Treatment Option

Initial Surgical AVR Improves Long-term Outcomes in Asymptomatic Patients With Severe AS

Cell Therapy for CHF

Gene Therapy for CHF

CPulse

Case Introduction: A Decompensated Patient With Heart Failure and Hypotension

Latest Innovations in ECMO and Escalation of Therapy

Durable Ventricular Assist Devices: Current and Next-Generation Devices and Implantation Techniques

NuPulse iVAS - A Minimally Invasive Advanced CHF Device

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content